Astellas Touts Data From Early Test of Stem Cell-Derived Eye Therapy
Astellas Pharma announced early-stage data from its stem cell‑derived retinal therapy, aimed at treating age‑related macular degeneration (AMD). In a small cohort receiving the highest dose, patients showed statistically significant gains in best‑corrected visual acuity and no serious safety signals. The trial, a Phase 1/2 first‑in‑human study, enrolled 12 participants, with three receiving the high‑dose formulation. Astellas plans to expand the program into a pivotal Phase 3 trial later this year.
Novel Nanoparticle Therapy Using Manganese Could Improve Cancer Treatment
Researchers at the University of Michigan and MD Anderson have engineered a manganese‑based nanoparticle named CRYSTAL that activates the cGAS‑STING immune pathway without provoking systemic inflammation. Preclinical studies across several tumor models, including advanced triple‑negative breast cancer, demonstrated robust, sustained...
Mozza Foods Targets Late 2028 Launch for Soybean-Grown Casein
Mozza Foods, a California molecular‑farming startup, plans to commercialize casein proteins harvested from genetically engineered soybeans by late 2028, pending USDA field‑crop approval and an FDA GRAS filing. The company has raised roughly $24 million and is targeting a technical milestone...
Ultrasound Waves Rupture COVID-19 and Flu Viruses without Damaging Cells
Researchers at the University of São Paulo have shown that high‑frequency ultrasound waves (3–20 MHz) can rupture the envelopes of SARS‑CoV‑2 and H1N1 viruses while leaving human cells unharmed. The effect, termed acoustic resonance, exploits the spherical geometry of enveloped viruses,...
G-Link CAR-T Delivery Platform Showcased at ASGCT
Vyriad unveiled its G‑Link CAR‑T delivery platform at the ASGCT meeting, showcasing a modular protein adapter that repurposes existing lentiviral vectors for in‑vivo use. The technology promises to cut development timelines by eliminating extensive vector redesign and to boost transduction...
FDA Approval of DOR/ISL Expands HIV Treatment Options Beyond INSTIs: Amy Colson, MD, MPH
The FDA has approved Idvysno, a two‑drug regimen of doravirine and islatravir (DOR/ISL), marking the first HIV therapy that omits both integrase strand transfer inhibitors (INSTIs) and tenofovir. Clinical trials showed non‑inferior viral suppression at 48 weeks compared with standard...
Polygenic Risk Score Predicts Eight Cardiovascular Conditions
A new polygenic risk score (PRS) predicts eight cardiovascular conditions, including coronary artery disease and atrial fibrillation, with odds ratios as high as 41.0. The assay, orderable from a blood or saliva sample, was validated in 53,306 participants and demonstrated...
Early Postoperative Inflammatory Markers Predict Major Complications After Rectal Cancer Surgery
A prospective cohort of 98 rectal cancer patients measured CRP and NLR at 24 and 48 hours after surgery. Elevated CRP at 48 hours strongly predicted major complications, while NLR showed no significant predictive value. Open surgery was linked to...
The BioPharm Brief: Breakthrough Signals in Cancer, Duchenne, and RNA Medicine
Aptevo Therapeutics reported an 87% clinical benefit rate and 81% remission in its Phase 1b AML RAINIER study, combining mipletamig with venetoclax and azacitidine. Entrada Therapeutics disclosed positive Phase 1/2 data for ENTR‑601‑44, showing functional gains and increased dystrophin in Duchenne patients...
Gene Therapy Restores Walking After Paralysis
Researchers at the University Hospital Cologne used a designer cytokine, hyper‑interleukin‑6 (hIL‑6), delivered via an AAV2 viral vector into the motor cortex of mice with spinal‑cord contusions. The protein traveled transneuronally to brainstem serotonergic neurons, prompting intact fibers to sprout...
DUET Trial: Low-Sodium Oxybate Significantly Consolidates Nighttime Sleep Architecture in Narcolepsy
The phase‑4 DUET trial showed that low‑sodium oxybate (LXB, Xywav) markedly consolidates nighttime sleep in narcolepsy type 1 and type 2 patients. Objective polysomnography recorded a 45‑minute increase in deep N3 sleep, 13 fewer stage transitions and three fewer awakenings per night....
Human Antibodies Identified That Have Potential To Prevent and Treat Measles Virus
Scientists at the La Jolla Institute for Immunology have isolated the first human monoclonal antibodies that can neutralize measles virus. The antibodies, derived from a vaccinated donor, bind the virus' hemagglutinin and fusion proteins, blocking entry into cells. In a...
Cellular Origins Collaborates with Immatics on Automation for Cell Therapy Manufacturing
Cellular Origins has partnered with immuno‑oncology firm Immatics to integrate its Constellation® automated mobile robotic platform into select steps of Immatics’ cell‑therapy manufacturing workflow. The joint effort will test how robotics can boost efficiency, scalability and cost‑effectiveness for next‑generation therapies,...
Stem Cell-Derived Islet Therapies Target Type 1 Diabetes Challenges
Sana Biotechnology is leveraging hypoimmune cell engineering to create allogeneic, stem‑cell‑derived pancreatic islet‑like cells that can evade both adaptive and innate immune attacks. The company aims to deliver a single intramuscular injection that restores normal blood‑sugar control for type 1 diabetes...
Aptevo Reports Strong Remission Data in Frontline AML Trial as RAINIER Study Advances Toward Phase 2
Aptevo Therapeutics disclosed Phase 1b data from its RAINIER trial, showing mipletamig combined with venetoclax and azacitidine achieved an 87% clinical benefit rate and an 81% composite remission rate in 31 frontline AML patients. The regimen produced a 65% complete remission...
Polyphasic in Vitro Characterization of the Pigment-Producing Microfungus Rhodotorula Sp. For Potential Application as a Probiotic in Mariculture
Researchers isolated a pigment‑producing Rhodotorula sp. from mangrove leaves in southern India and applied a polyphasic in‑vitro framework to assess its probiotic suitability for mariculture. The strain generated 0.73 g L⁻¹ dry biomass, accumulated up to 398 µg g⁻¹ carotenoids, and displayed strong antioxidant...
Just ‘Stay Alive for the Next 10 Years’ – Anti-Ageing Drugs Are Coming, Says Billionaire Investor
Billionaire investor Jim Mellon told attendees at Spear’s 500 Live that the first truly anti‑ageing drugs could hit the market within a decade. He highlighted clinical‑stage senolytics, partial genetic reprogramming and repurposed weight‑loss medicines as the leading candidates to halt...
EnGene's Shares Crash on Updated Pivotal Bladder Cancer Data
EnGene Therapeutics reported Phase 2 data for its experimental bladder‑cancer therapy that revealed a modest 5% objective response rate and safety signals in more than half of patients. The results triggered an 80% plunge in the Canadian biotech’s stock, wiping...
Blackstone Puts $250M Into Anagram to Tackle Cystic Fibrosis Complication
Blackstone Life Sciences announced a $250 million investment in Anagram, a biotech developing a novel therapy for a cystic fibrosis complication. The capital, drawn from one of the industry’s largest private life‑science funds, will accelerate Anagram’s late‑stage clinical trials, manufacturing scale‑up,...
Can OpenAI’s GPT Rosalind Tackle Data Challenges in Life Sciences Research?
OpenAI has unveiled GPT‑Rosalind, a large language model tailored for life‑science research that can reason across literature, biological databases, and experimental data. In internal tests the model led benchmark BixBench, showing superior multi‑step bioinformatics performance compared with earlier OpenAI models....
Entrada Stock Falls on Duchenne Data; Wegovy Expands Access
Entrada Therapeutics reported topline results from its Duchenne muscular dystrophy (DMD) cohort of six patients, showing no meaningful functional improvement. The disappointing data sent Entrada's shares down roughly 15% in after‑hours trading. Meanwhile, Novo Nordisk announced expanded payer coverage for...
Insmed Tanks On Its Most Important Launch; Why Analysts Remain Bullish
Insmed’s newly launched lung drug Brinsupri posted first‑quarter sales of $208 million, beating sell‑side forecasts but falling short of the $230 million buy‑side target. The miss triggered a near‑17% plunge in the stock, sending shares to $114.25, their lowest level since August....
Genetic Testing May Unlock Vitamin D's Potential for Diabetes Prevention
A JAMA Network Open analysis of the D2d trial shows that daily 4,000 IU vitamin D₃ reduced type 2 diabetes incidence by 19% among prediabetic adults carrying the ApaI AC or CC variants of the vitamin D receptor gene. The same high‑dose regimen had...
FDA Reverses Course on Atara, Pierre Fabre’s Twice-Rejected Cell Therapy After Prasad’s Exit
Atara Biotherapeutics and Pierre Fabre’s EBV‑positive PTLD cell therapy Ebvallo received a regulatory U‑turn after FDA CBER director Vinay Prasad stepped down. The agency now says a single‑arm study with an appropriate historical control can satisfy the “adequate and well‑controlled” requirement, allowing...
Electric‐Eel‐Inspired Ionic Power Source Microneedles With Self‐Reporting Structural Colors for Wound Healing
Researchers have engineered ionic power source microneedles (IPSMs) that combine electric‑eel‑inspired ion transport with chameleon‑like structural colors for wound care. The three‑layer device creates an internal K⁺‑driven electric field, delivering electrical stimulation that accelerates tissue repair. Integrated silver nanoparticles provide...
Transforming CTMS: An Operating Layer for Real-Time Trial Execution
Clinical trial management systems (CTMS) are evolving from static record‑keeping tools into an operating layer that adds real‑time, AI‑driven reasoning to coordinate complex, multi‑system studies. The article highlights that Phase III trials now span a median of more than ten countries,...
3D-MIND: A Flexible Device that Can Be Integrated with Living Brain Cells
Researchers at Princeton have unveiled 3D-MIND, a flexible electronic mesh that can be embedded inside three‑dimensional cultures of living brain cells. The device integrates sensors and micro‑stimulators within the neural tissue, enabling stable recording and stimulation for up to six...
Funding Roundup: Kanvas Biosciences, LTZ Therapeutics Draw Investor Interest for Next-Generation Cancer Immunotherapies
Kanvas Biosciences and LTZ Therapeutics announced a combined $86 million financing round to accelerate next‑generation cancer immunotherapies. Kanvas closed a $48 million Series A to push its microbiome‑based platform and the lead candidate KAN‑001 toward clinical trials. LTZ secured $38 million to expand its...
Amgen Adds $300M to Puerto Rico Budget; Novartis to Exit Oral Drug Factory in Germany
Amgen announced an additional $300 million investment to expand its manufacturing footprint in Puerto Rico, bringing its total U.S. capital outlay to nearly $2 billion over the past year. The funding will support new bioprocessing lines and increase the island’s capacity for...
Breaking Down Frontline BTK Inhibitor Selection in CLL: Kerry Rogers, MD
When choosing a frontline Bruton tyrosine kinase (BTK) inhibitor for chronic lymphocytic leukemia, clinicians currently rely on FDA‑approved covalent agents, with acalabrutinib and zanubrutinib favored for their superior cardiovascular safety over ibrutinib. Emerging data from the 2025 ASH meeting show...
STAT+: Pharmalittle: We’re Reading About Sanofi and an FDA Voucher, FDA Rethinking a Rejection, and More
Sanofi asked the FDA to withdraw its type 1 diabetes antibody teplizumab from the new fast‑track voucher program after Center for Drug Evaluation and Research director Tracy Beth Høeg publicly challenged a staff decision to approve the drug. The agency missed...
Entrada Crashes as Duchenne Therapy Comes in ‘Below Expectations’ in Early Study
Entrada Therapeutics reported that its investigational oligonucleotide ENTR‑601‑44 raised dystrophin levels by 2.36% in the first cohort of its Phase 1/2 ELEVATE‑44‑201 trial, far below the company’s double‑digit target. The modest protein increase triggered a 50% plunge in the Boston‑based biotech’s...
Podcast: Autonomous Labs Redefine the Role of Biopharma Researchers
Autonomous laboratories, integrating robotic hardware with AI-driven decision making, are emerging as a transformative force in biopharma R&D. In a GlobalData Media podcast, Frankie Fattorini interviewed Jason Kelly, CEO of Ginkgo Bioworks, who described how these labs can conduct experiments with unprecedented precision...
Studying These Young Alzheimer's Patients Led to Breakthroughs. Trump Cut the Funding
The Dominantly Inherited Alzheimer Network (DIAN) has leveraged over 200 families with rare early‑onset Alzheimer’s gene mutations to uncover how the disease begins and to test amyloid‑targeting drugs that later reached the market. Its international registry, funded by the NIH...
STAT+: FDA Revisits a Rare Cancer Treatment It Rejected a Few Months Ago
The FDA has announced it will re‑evaluate a rare‑cancer therapy it dismissed just months earlier, citing new data submitted by the drug’s sponsor. The treatment, aimed at a subtype of metastatic sarcoma, originally failed to meet the agency’s efficacy benchmarks...
Amylyx Pharmaceuticals Q1 Earnings Call Highlights
Amylyx Pharmaceuticals reported that the Phase 3 LUCIDITY trial of its GLP‑1 antagonist avexitide completed dosing and is on track for a top‑line readout in Q3 2026. The company launched a U.S. expanded access program to treat up to 250 adults with...
Atara, Pierre Fabre's Cell Therapy to Get Another Shot at FDA Approval
Atara Biotherapeutics and Pierre Fabre Pharmaceuticals are reviving a T‑cell therapy that was rejected twice by the FDA. Regulators have signaled willingness to base a new approval decision on data from a Phase 3 trial, a departure from the earlier requirement...
Wolfe Research Says Market Reaction on Eli Lilly (LLY) Foundayo Report Appears Overdone
Wolfe Research says the market overreacted to an FDA adverse‑event report on Eli Lilly’s GLP‑1 drug Foundayo. Lilly determined the serious hepatic failure case was not reasonably related to the product. Shares fell about 3% in pre‑market trading, yet analysts kept...
‘People Should Be Talking About It’: Moves to Curtail Vaccine Information Obscures Important Science, Doctors Say
U.S. health agencies, including the FDA, CDC and NIH, have halted or censored several vaccine studies and presentations in 2026, citing methodological concerns or political language guidelines. A leaked Covid‑19 booster effectiveness study, pulled at the last minute, still shows...
The Rise of Trispecific Antibodies: Biopharma’s Next Big Bet After Bispecifics
Trispecific antibodies are emerging as the next wave of multispecific therapeutics, extending the success of bispecifics by simultaneously engaging three targets. More than 100 candidates are now in clinical trials, with major players such as Pfizer, Sanofi, AbbVie and Johnson...
Treatment-Resistant IBD May Benefit From New Combo Antibody Therapy
Phase 2b DUET‑Crohn’s and DUET‑UC trials, funded by Johnson & Johnson, tested the fixed‑dose co‑antibody JNJ‑4804 (guselkumab + golimumab) in patients whose IBD had failed prior advanced therapies. In ulcerative colitis, JNJ‑4804 matched guselkumab’s efficacy and outperformed golimumab, while in Crohn’s disease the highest dose...
Bayer Reports P-III (REVEAL) Trial Data on Iodine 124 Evuzamitide to Diagnose Cardiac Amyloidosis
Bayer announced that its investigational PET/CT radiotracer I‑124 evuzamitide met the primary sensitivity and specificity endpoints in the Phase III REVEAL trial of 170 adults with suspected cardiac amyloidosis. The study compared the tracer to standard clinical diagnosis and achieved the...
Sarepta Says to ‘Exercise Prudence’ in Setting Expectations for Elevidys’ Recovery
Sarepta Therapeutics urged analysts to "exercise prudence" as it navigates a turbulent recovery after three patient deaths linked to its Duchenne muscular dystrophy gene therapy Elevidys. The FDA imposed a boxed warning and limited the drug to ambulatory patients aged...
Silence Therapeutics Highlights Recent Business Achievements and Reports First Quarter 2026 Financial Results
Silence Therapeutics reported Q1 2026 results, ending the quarter with $70.1 million in cash and a net loss of $15 million, a sharp improvement from the $28.5 million loss a year earlier. The company highlighted progress on its lead siRNA candidate divesiran, with Phase 2...
Unlocking Lithium’s Hidden Effects on Alzheimer’s Disease at the Cellular Level
A University of Eastern Finland team mapped lithium chloride’s cellular actions in Alzheimer’s models, showing it reduces Tau hyperphosphorylation at several key sites and reshapes kinase and Rho GTPase signaling. Phosphoproteomic analysis revealed lithium’s impact extends beyond the primary GSK‑3β...
Six-Month Trial Confirms Safety of Previously Uncharacterized Probiotic Strain
A six‑month, double‑blind trial involving 152 healthy adults found that daily consumption of Lactiplantibacillus plantarum K014 (≥1 × 10⁹ CFU) was safe, with blood counts, glucose, lipid, liver and kidney markers remaining within normal ranges. No adverse events were reported, and exploratory analyses suggested...
NIH-Funded Study Suggests that Testosterone Suppresses Brain Tumor Growth in Males
A NIH‑funded study by Cleveland Clinic researchers found that loss of male hormones, especially testosterone, accelerates glioblastoma growth in mouse models by triggering inflammation and the hypothalamus‑pituitary‑adrenal (HPA) stress axis. Supplemental testosterone was associated with a 38% lower risk of...
Magic Mushroom Compound Shows Promise Against Cocaine Addiction
A randomized, double‑blind trial of psilocybin in 40 cocaine‑dependent adults, published in JAMA Network Open, found that 30% of participants receiving a single dose were completely abstinent after 180 days, compared with none in the placebo arm, and remaining users...
STAT+: Next-Gen Duchenne Drug From Entrada Disappoints
Entrada Therapeutics reported that its next‑generation exon‑skipping drug for Duchenne muscular dystrophy failed to achieve its primary efficacy endpoints in an early‑stage trial. The study showed only a modest rise in dystrophin levels, far below the thresholds set by the...
Entrada Shares Sink After Duchenne Drug Falls Short of Expectations
Entrada Therapeutics reported that its experimental Duchenne drug ENTR-601-44 generated only a 2.36‑point increase in dystrophin, far below the 10‑11% rise analysts had modeled. The shortfall sent the company’s shares tumbling more than 50% in pre‑market trading. By contrast, Avidity...